-
Product Insights
NewNet Present Value Model: Vaxcyte Inc’s VAX-24
Empower your strategies with our Net Present Value Model: Vaxcyte Inc's VAX-24 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Vaxcyte Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Vaxcyte Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VAX-31 in Streptococcal Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VAX-31 in Streptococcal Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VAX-31 in Streptococcal Pneumonia Drug Details: VAX-XP is under development for the...
-
Product Insights
Impetigo – Drugs In Development, 2023
Global Markets Direct’s, ‘Impetigo - Drugs In Development, 2023’, provides an overview of the Impetigo pipeline landscape. The report provides comprehensive information on the therapeutics under development for Impetigo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Otitis Media – Drugs In Development, 2023
Global Markets Direct’s, ‘Otitis Media - Drugs In Development, 2023’, provides an overview of the Otitis Media pipeline landscape. The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Bacillary Dysentery (Shigellosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Bacillary Dysentery (Shigellosis) - Drugs In Development, 2023’, provides an overview of the Bacillary Dysentery (Shigellosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Periodontal Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Periodontal Disease - Drugs In Development, 2023’, provides an overview of the Periodontal Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Periodontal Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Streptococcal Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Streptococcal Pneumonia - Drugs In Development, 2023’, provides an overview of the Streptococcal Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azenosertib in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Epithelial Ovarian Cancer Drug Details: Azenosertib (ZNC-3) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VAX-24 in Streptococcal Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VAX-24 in Streptococcal Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VAX-24 in Streptococcal Pneumonia Drug Details:VAX-24 is under development for the prevention of...